Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 13/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL318190 | 1.00 | LMNA (0.49) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL318058 | 0.79 | LMNA (0.47) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL10108810 | 0.79 | LMNA (0.47) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL318173 | 0.79 | LMNA (0.47) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL10108843 | 0.79 | LMNA (0.47) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL5266396 | 0.77 | KDM4E (0.56) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL6556471 | 0.77 | GAA (0.45) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL6556481 | 0.77 | GAA (0.45) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL6556478 | 0.77 | GAA (0.45) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL10109092 | 0.74 | LMNA (0.43) | LMNAGAACYP19A1MAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | LMNA 2755/4885GAA 2018/4885CYP19A1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.